RxDoctor Payments Data

Gustavo Marks, MD

Family Medicine · Canoga Park, CANPI 1740373315

Payments from drug & device makers

$3,148in general payments, 2019–2025

Across 126 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$614
  • Lilly USA, LLC$517
  • Boehringer Ingelheim$361
  • Novo Nordisk$317
  • AbbVie$235
  • Biohaven Pharmaceuticals, Inc.$170
  • plus $935 from 14 others

What the payments were for

  • Food & beverage$3,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,148 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$91,845
Medicare patients
100
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide12$21,084
FarxigaDapagliflozin Propanediol14$12,646
EliquisApixaban13$3,783
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,249
Ventolin HfaAlbuterol Sulfate15$1,037
Levothyroxine Sodium64$742
Omeprazole47$688
Atorvastatin Calcium67$556
Albuterol Sulfate HfaAlbuterol Sulfate11$493
Amlodipine Besylate34$486
Losartan Potassium50$473
Alprazolam62$392
Rosuvastatin Calcium14$377
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide25$374
Pilocarpine Hcl12$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$517$21,08412 claims
AstraZenecaFarxiga$614$12,64614 claims
PfizerEliquis$68$3,78313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Canoga Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →